In a major announcement, an experimental mRNA vaccine has been shown in global clinical trials to prevent melanoma from returning or spreading in high-risk melanoma patients when combined with the immunotherapy drug pembrolizumab, known commercially as Keytruda, and given after surgery.
mRNA-Based Therapy Offers New Hope Against High-Risk Melanoma
View Content